3SBIO (01530) experienced a sharp intraday decline of 13.14%, reflecting a broader downturn in the innovative drug sector during the trading session.

The selloff was driven by persistent geopolitical uncertainties and rising oil prices, which have boosted inflation expectations and subsequently limited the potential for interest rate cuts. A report highlighted that global innovative drug financing declined by 7.1% year-on-year in 2025, influenced by these global pressures and the pace of U.S. Federal Reserve monetary policy adjustments.

While the report noted a potential recovery in financing volume and suggested that a subsiding U.S.-Iran conflict coupled with continued Fed rate cuts could support a rebound in 2026, the immediate market sentiment weighed heavily on biopharma stocks like 3SBIO during the session.